Cancer Network spoke with Ruth Oratz, MD, a medical oncologist at NYU Langone Perlmutter Cancer Center in New York City, about the use of PARP inhibitors for breast cancer.
Ruth Oratz, MD
Advertisement
Articles by Ruth Oratz, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Does Patient Selection Inflate CAR T Outcomes in Multiple Myeloma?
2
Changing Chemotherapy Delivery in BCG-Unresponsive Bladder Cancer
3
Why CAR T-Cell Therapy Should Precede Bispecifics in Multiple Myeloma
4
Tisagenlecleucel Shows Durable Efficacy in Pediatric/Young Adult ALL
5